Synchron

Type: Company (Minimally Invasive BCI)

Synchron occupies the middle ground in the brain-computer interface landscape with its Stentrode device — a stent-based electrode array delivered through the jugular vein and positioned in a blood vessel adjacent to the motor cortex. This endovascular approach avoids the craniotomy required by intracortical arrays like Neuralink's N1, dramatically reducing surgical risk and recovery time.

The Stentrode has been demonstrated controlling an iPad through thought — a patient was able to send messages, browse the web, and perform other tablet interactions using neural signals decoded from the device. While the signal bandwidth is lower than intracortical arrays (the electrodes sit outside the brain rather than within it), the reduced invasiveness makes the risk-benefit calculation favorable for a broader patient population.

Synchron's competitive position is that they offer "good enough" neural signal quality without brain surgery. For many patients, especially those who might not qualify for or choose to undergo craniotomy, this tradeoff is compelling. The company is positioning for a larger addressable market than pure intracortical approaches.

COMMAND Feasibility Trial Results

• 12-month safety and efficacy data from 6 patients with severe chronic bilateral upper-limb paralysis (COMMAND; NCT05035823; three US sites; NIH BRAIN Initiative–supported)
• Primary endpoint met — no device-related serious adverse events (death or permanent increased disability) over 12 months. COMMAND was the first US FDA-approved IDE trial of a permanently implanted BCI
• No serious adverse events related to the brain or vasculature; target motor-cortex coverage achieved in all six
• Proven long-term stability — 12+ months without repositioning
• $200M Series D (announced Nov 6, 2025) secured for the pivotal trial + first-gen commercial prep

2026 Pivotal Trial — Path to the First BCI PMA

Synchron is preparing a pivotal clinical trial in 2026 — the study it must clear before filing the first-ever FDA premarket approval (PMA) for a permanently implanted brain-computer interface. If the pivotal succeeds, Synchron would be the first company positioned to file such a PMA. The strategy is lowest surgical risk + first to a filing, addressing tens of thousands of Americans with severe paralysis from ALS, stroke, or spinal cord injury. The company has also signalled a next-generation interface with "potentially more applications." Market entry remains potentially 2028–2029 if the pivotal succeeds.

Key Contributions

• Stentrode: endovascular BCI delivered through jugular vein, no craniotomy (Non-Invasive BCI)
• iPad control demonstration — messaging, browsing through thought (Non-Invasive BCI)
• COMMAND 12-month primary endpoint met, 6 patients, NCT05035823 (Stentrode Primary Endpoint)
• 2026 pivotal trial → first BCI PMA filing pathway (Synchron pivotal)
• $200M Series D (Nov 2025) for pivotal trials + commercial prep (Synchron pivotal)

Mentioned In

• Invasive vs. Non-Invasive BCI — Minimally invasive tier example
• Neuroprosthetics — Alternative approach to motor function restoration
• Neural Signal Decoding — Medium-bandwidth signal source
• Invasive BCI Devices — Stentrode feasibility trial and pivotal trial plans
• BCI Clinical Applications — Motor paralysis and communication restoration
• BCI Signal Acquisition — Endovascular (intervention tier) acquisition approach

Related Entities

• Neuralink — Invasive (intracortical) BCI competitor
• Paradromics — High-bandwidth intracortical competitor; opposite end of the invasiveness ↔ bandwidth axis

Changelog

• 2026-04-14 — Created from non-invasive bioelectronics + Stentrode primary-endpoint sources
• 2026-06-24 — Named the COMMAND trial (NCT05035823, NIH BRAIN Initiative, first FDA-IDE permanent-implant BCI); added the 2026 pivotal trial → first BCI PMA pathway and next-gen interface; dated Series D (Nov 6 2025); linked Paradromics